Risperidone (QUAR)

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 1 (1)
Schizophrenia
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Schizophrenia
NCT00857818 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-04 – 2010-03 · Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
What this study did
Phase 2 (2)
Schizophrenia
NCT04624243 · Merck Sharp & Dohme LLC
2020-12-15 – 2024-06-21 · Schizophrenia
What this study did
NCT03055338 · Merck Sharp & Dohme LLC
2017-03-08 – 2018-01-09 · Schizophrenia, Acute Episode
What this study did
Phase 1 (3)
Schizophrenia
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
NCT01376076 · Forest Laboratories
2011-06 – 2012-02 · Schizophrenia
What this study did
Appears in other studies (21)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (10)
Schizophrenia
NCT06878833 · Lyndra Inc.
2025-04-18 – 2026-12-31 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01370291 · Xijing Hospital
2011-06 – 2013-12 · Schizophrenia
What this study did
NCT00843687 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-09 – 2007-03 · Schizophrenia
What this study did
NCT00216580 · Janssen Pharmaceutica N.V., Belgium
2004-02 – 2006-12 · Schizophrenia
What this study did
NCT00828958 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-02 – 2006-09 · Schizophrenia
What this study did
NCT00237913 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-07 – 2005-08 · Schizophrenia
What this study did
NCT00034892 · AstraZeneca
2002-03 – 2005-03 · Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
What this study did
NCT00161018 · University of Maryland, Baltimore
2003-11 – 2004-11 · Schizophrenia
What this study did
NCT00159770 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2001-11 – 2004-09 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
What this study did
NCT00297388 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
est. completion 2004-09 · Schizophrenia, Schizoaffective Disorder
What this study did
Phase 2 (4)
Schizophrenia
NCT07152184 · University Hospital, Strasbourg, France
2026-10-01 – 2032-02-01 · Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
What this study did
NCT01411085 · Dartmouth-Hitchcock Medical Center
2011-12 – 2014-09 · Schizophrenia, Alcoholism, Dual Diagnosis
What this study did
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
NCT00921804 · AstraZeneca
2009-06 – 2010-05 · Schizophrenia
What this study did
Phase 1/2 (1)
Schizophrenia
NCT02538081 · VA Office of Research and Development
2015-08 – 2016-08 · Schizophrenia
What this study did
Early phase / not applicable (6)
Schizophrenia
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did
NCT00716755 · Centre for Addiction and Mental Health
2009-10 – 2015-08 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder, Psychotic Disorder
What this study did
NCT00493233 · Centre for Addiction and Mental Health
2006-11 – 2008-12 · Schizophrenia
What this study did
NCT00225498 · Northwell Health
2002-06 – 2008-10 · Schizophrenia
What this study did
NCT00179062 · Vanderbilt University
2000-02 – 2007-06 · Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
What this study did
NCT00205738 · Washington University School of Medicine
2000-07 – 2006-10 · Schizophrenia, Type 2 Diabetes Mellitus
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, 23 of them ahead of this one.

This drug's own stage for Schizophrenia: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Risperidone (QUAR): this drugPhase 1Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)Reliable signal
NCT03172871: LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin
NCT00706654: Impending relapse by week 26: aripiprazole once-monthly 400 mg 7.12% vs oral aripiprazole 10-30 mg 7.76% (non-inferior); low-dose depot reference arm 21.80%
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT00712686: Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05).
Aripiprazole Lauroxil (Aristada Initio)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole Lauroxil (Aristada)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorReliable signal
NCT01469039: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39)
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00212771: Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint
NCT00212784: Change in total PANSS score (52-week active-controlled trial): asenapine -21.0 vs olanzapine -27.5, difference P<0.0001. missed
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT03198078: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014
NCT01396421: Change in PANSS total score at Week 6 vs placebo: brexpiprazole 2 mg treatment difference -8.72; 4 mg treatment difference -7.64 (both statistically significant).
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Reliable signal
NCT01104766: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4)
NCT01104779: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline to Week 6): Cariprazine (3-6 mg/Day) -22.8 Units on a Scale (Standard Error 1.6) | Cariprazine (6-9 mg/Day) -25.9 Units on a Scale (Standard Error 1.7) vs Placebo -16 Units on a Scale (Standard Error 1.6)
ClozapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT03510325: Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed.
Haloperidol
ApprovedUS marketing discontinued
Small moleculeDopamine D2 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00254202: Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2).
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorPartial signal
NCT04959032: Study 304 (NCT04959032), time to relapse during double-blind phase: HR 0.37 (95% CI 0.22-0.65), 63% relapse-risk reduction vs placebo (p=0.0002); relapse rate 16.4% (18 relapses) lumateperone vs 38.6% (44 relapses) placebo
NCT02469155: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks): Lumateperone 14 mg (ITI-007 20 mg Tosylate) -15 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.6 units on a scale (Standard Error 1.23) vs Placebo -15.1 units on a scale (Standard Error 1.21) | Risperidone -20.5 units on a scale (Standard Error 1.33) missed
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03465787: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority.
NCT00549718: Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks): Lurasidone 40mg -19.2 scores on a scale (95% CI -22.6 to -15.7) | Lurasidone 80mg -23.4 scores on a scale (95% CI -26.9 to -19.9) | Lurasidone 120mg -20.5 scores on a scale (95% CI -24 to -17.1) vs Placebo -17 scores on a scale (95% CI -20.5 to -13.6)
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Weltruza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Reliable signal
NCT05693935: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8): Double-blind: TV-44749 318 mg -21.91 units on a scale (95% CI -25.13 to -18.7) | Double-blind: TV-44749 425 mg -23.44 units on a scale (95% CI -26.52 to -20.36) | Double-blind: TV-44749 531 mg -21.93 units on a scale (95% CI -25.01 to -18.85) vs Double-blind: Placebo -12.17 units on a scale (95% CI -15.34 to -8.99)
Olanzapine (Zyprexa Relprevv)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00088478: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each).
NCT00320489: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) (Baseline up to 104 weeks): Olanzapine Pamoate Depot 644.5 Days (IQR 162 to 740) vs Oral Olanzapine 677.5 Days (IQR 169.5 to 740) missed
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT03510325: Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 missed
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signal
NCT03187769: Percent change from baseline in body weight at Week 12: 4.91% ALKS 3831 vs 6.77% olanzapine; least-squares mean difference −1.87 percentage points (95% CI −3.33 to −0.41; p=0.012).
NCT02634346: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks): ALKS 3831 -23.9 units on a scale (Standard Error 1.28) vs Olanzapine -22.8 units on a scale (Standard Error 1.29) vs Placebo -17.5 units on a scale (Standard Error 1.32)
Paliperidone (Invega)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet graded
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 phase 3 result · pivotal pending
Paliperidone Palmitate (Erzofri)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (Invega Sustenna)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT02431702: Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). missed
NCT00101634: PANSS total improved vs placebo in all three fixed-dose groups (p=0.02 for 25 and 50 mg equiv., p<0.001 for 100 mg equiv.).
Paliperidone Palmitate (Invega Trinza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178
NCT02713282: Symptomatic remission (Andreasen PANSS criteria) at LOCF/Month 12 endpoint: 172/303 patients, 56.8% (95% CI 51.0-62.4)
Perseris
ApprovedUS marketing discontinued
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT02109562: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT00640601: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8)
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00305422: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00253136: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly.
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03503318: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181
Xanomeline / Trospium Chloride (Cobenfy)ApprovedSmall moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)Reliable signal
NCT04738123: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5): KarXT -20.6 Score on a scale (Standard Error 1.584) vs Placebo -12.2 Score on a scale (Standard Error 1.552)
NCT04659161: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5): KarXT -21.2 score on a scale (Standard Deviation 1.652) vs Placebo -11.6 score on a scale (Standard Deviation 1.6)
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00403546: Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). missed
NCT00159770: Ziprasidone non-inferior to the olanzapine/risperidone/quetiapine group on total PANSS (margin 7 units; P<0.0001).
Cariprazine (Chengdu Kanghong)Phase 3Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (QLM1016)Phase 3Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signal
NCT04268303: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours): 120 Micrograms — Baseline: 17.5 score on a scale (Standard Deviation 2.46); 2 Hours: -8.4 score on a scale (Standard Deviation 4.83) | 180 Micrograms — Baseline: 17.6 score on a scale (Standard Deviation 2.69); 2 Hours: -10.4 score on a scale (Standard Deviation 4.34) vs Placebo — Baseline: 17.6 score on a scale (Standard Deviation 2.26); 2 Hours: -4.7 score on a scale (Standard Deviation 4.69)
NCT05658510: Primary endpoint (SERENITY III Part 1, change from baseline in PEC total score at 2 hours), drug vs placebo: p=0.077, not statistically significant.
DireclidinePhase 3Small moleculeMuscarinic M4 receptorPartial signal
NCT05545111: PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline
HS-10380Phase 3Small moleculeDopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target)Partial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)Phase 3Small moleculeDopamine D2/D3 receptor + 5-HT7 receptorReliable signal
NCT06179108: Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): LB-102, 50 mg QD -14.28 score on a scale ± 1.097 vs LB-102, 75 mg QD -13.95 score on a scale ± 1.108 vs LB-102, 100 mg -16.08 score on a scale ± 1.906 vs Placebo Comparator -9.27 score on a scale ± 1.078; p=0.0009 (LB-102, 50 mg QD vs Placebo Comparator), p=0.0022 (LB-102, 75 mg QD vs Placebo Comparator), p=.0017 (LB-102, 100 mg vs Placebo Comparator)
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00628589: Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92)
Olanzapine / Samidorphan (Qilu)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist), Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
RoluperidonePhase 3Small moleculeSigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist)Partial signal
NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed
UlotarontPhase 3Small moleculeTAAR1 (trace amine-associated receptor 1)Partial signal
NCT04092686: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): SEP-363856 75mg -16.4 score on a scale (Standard Error 1.49) | SEP-363856 100mg -18.1 score on a scale (Standard Error 1.5) vs Placebo -14.3 score on a scale (Standard Error 1.47) missed
NCT04072354: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): Adults: SEP-363856 50mg -16.9 score on a scale (Standard Error 1.57) | Adults: SEP-363856 75mg -19.6 score on a scale (Standard Error 1.56) vs Adults: Placebo -19.3 score on a scale (Standard Error 1.55) missed
ANAVEX3-71Phase 2Small moleculeSigma-1 receptor / muscarinic receptor (dual)Partial signal
NCT06245213: ANAVEX3-71-SZ-001 (NCT06245213) achieved its primary endpoint: ANAVEX3-71 was safe and well-tolerated, with no serious TEAEs and no severe TEAEs in either Part A or Part B.
Balipodect (TAK-063)Phase 2Small moleculePhosphodiesterase 10A (PDE10A)Partial signal
NCT02477020: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 (Baseline and Week 6): TAK-063 -19.54 score on a scale (Standard Error 2.412) vs Placebo -14.08 score on a scale (Standard Error 2.474) missed
Betovumeline / Fesoterodine (ML-007C-MA)Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)Partial signal
NCT07038876: PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed.
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CPL500036Phase 2Small moleculePDE10AReliable signal
NCT05278156: Change from baseline in PANSS positive subscale at Day 28 (Week 4): 20 mg dose improved 3.7 points (p<0.001, Cohen's d=0.73); 40 mg dose improved 6.3 points (p<0.001, Cohen's d=1.38)
EmraclidinePhase 2Small moleculeMuscarinic M4 receptorPartial signal
NCT05227703: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) missed
GXV813Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
LY03020Phase 2Small molecule5-HT2C/TAAR1 receptorWeak signalNo reviewed efficacy summary in this indication
NBI-1117570Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2Small moleculeDendritic spine densitynot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VV119Phase 2Small moleculeDopamine and serotonin receptors (multi-target antipsychotic)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine Long-Acting Injection (Mapi Pharma)Phase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
JX11502MAPhase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)Weak signal
NCT05233657: JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%).
AticaprantPhase 1Small moleculeKappa-opioid receptor (inhibitor), Kappa opioid receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole Long-Acting Injection (Kelun)Phase 1Small moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
HS-10509Phase 1Small molecule—Partial signalNo reviewed efficacy summary in this indication
LY03017Phase 1Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptorWeak signalNo reviewed efficacy summary in this indication
NTX-253Phase 1Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (CSPC)
—(overall)
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)Weak signal
NCT03892889: Percentage of Participants With Inpatient Psychiatric Hospitalization (Retrospective Period [Month -6 to Baseline (Day 1)] up to Prospective Period (Day 1 to Month 3)): Abilify MyCite® 0%
AVP-786DiscontinuedCombinationsigma-1/NMDAnot yet gradedNo reviewed efficacy summary in this indication
Clozapine (Fazaclo)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Extended-Release Niacin (Niaspan)DiscontinuedSmall moleculeGPR109A (HCAR2)not yet gradedNo reviewed efficacy summary in this indication
NeloniclineDiscontinuedSmall moleculenicotinic acetylcholine receptor alpha7 (alpha7 nAChR)Partial signal
NCT01655680: MCCB neurocognitive composite, change from baseline to week 12 (primary analysis, ABT-126 50 mg vs placebo): +2.66 (±0.54) vs +2.46 (±0.56), P>0.05; 432 randomized. The UPSA-2ER key secondary also showed no significant difference. missed
Risperidone (Risvan)DiscontinuedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03160521: PANSS Total Score Mean Change From Baseline to Endpoint (Day 1 (Baseline) and Day 85 (or the last post-baseline assessment)): Risperidone ISM 75 mg -24.6 units on a scale (Standard Error 1.51) | Risperidone ISM 100 mg -24.7 units on a scale (Standard Error 1.54) vs Placebo -11 units on a scale (Standard Error 1.56)
Rosiglitazone (Avandia)DiscontinuedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.